May 28, 2026
National Cancer Institute (NCI)
The purpose of this Notice is to extend the expiration date for PAR-25-095, "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)".
Therefore, with the addition/extension by one Application Due Date, PAR-25-095 now expires on November 6, 2026.
The following sections in Part 1. Overview Information, Key Dates section have been changed:
Currently reads and modified to read (in bold italics):
| New | Renewal/ Resubmission/ Revision | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
| February 5, 2025 | March 5, 2025 | Not Applicable | July 2025 | October 2025 | December 2025 |
| June 5, 2025 | July 5, 2025 | Not Applicable | November 2025 | January 2026 | April 2026 |
| October 5, 2025 | November 5, 2025 | Not Applicable | March 2026 | May 2026 | July 2026 |
| February 5, 2026 | March 5, 2026 | Not Applicable | July 2026 | October 2026 | December 2026 |
| June 5, 2026 | July 5, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 5, 2026 | November 5, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
Currently reads:
Expiration Date: September 08, 2026
Modified to read (in italics):
Expiration Date: November 6, 2026
All other aspects of PAR-25-095 remain unchanged.
Please direct all inquiries to:
Email: [email protected]